In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner.
The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia.
* * *
Help us make this podcast better! Please take this short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019
* * *
ISCHEMIA trial hailed as practice changing
The results of the ISCHEMIA trial were emphatically declared practice changing by interventional cardiologists and noninterventionalists alike at the AHA meeting.
Bruce Jancin discusses the story.
DAPA-HF: Dapagliflozin's HFrRF efficacy confirmed in nondiabetes
The results in nondiabetics from the practice-changing DAPA-HF trial gives clinicians strong evidence that the diabetes drug dapagliflozin is equally effective at reducing cardiovascular death and acute exacerbations in heart failure patients regardless of diabetes status.
Mitchel L. Zoler discusses this report.
Weakness exposed in valsartan recall
ED visits for hypertension in the month after the 2018 recall spiked 55%. The 2018 recall of generic forms of the antihypertensive drug valsartan exposed weaknesses in the recall systems for generics in both the U.S. and Canada that caused many patients who were on the drug to fall through the cracks.
Richard Mark Kirkner goes deeper into this story.
* * *
For full coverage of AHA 2019 visit MDedge Cardiology
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeCardio
Top stories from the American Heart Association scientific sessions
Vascepa gains event-reduction nod; diabetes ups ischemic risks
Post-STEMI events less likely in women; bariatric surgery may lower stroke risk
New trick for old drug; Vascepa cost effective for CV reduction
Card Talk: TAVR and glass ceilings
Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF
Pot heightens stroke, arrhythmia risks; keeping low LDL and BP slashes lifetime heart risk
How risk factors in childhood translate to CV outcomes in adulthood
Driving while defibrillating; hypertension holds greater risk in black patients
AFib hits Native Americans hard; TAVR shown durable, safe after 5 years
Practice changing prevention data from ESC 2019 Part II
Statins tied to skin, soft tissue infections; new Card Talk episode
Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis
Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk
Cardiology dead last as women’s IM subspecialty choice
An antiplatelet surprise; Europeans go low in cholesterol guidelines
SGLT-2 inhibitors and more practice changing data from ESC 2019
Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment
Dapagliflozin transforms into heart failure drug
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive